Y-Intercept (HK)’s Kyverna Therapeutics KYTX Stock Holding History

Y-Intercept (HK)’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.16M	Buy	242,387 +127,546	+111%	+$1.13M	0.04%	655
2026 Q1	$991K	Buy	+114,841	New	+$957K	0.02%	1033
2025 Q3	–	Sell	-42,025	Closed	-$129K	–	2129
2025 Q2	$129K	Buy	+42,025	New	+$104K	﹤0.01%	1513

Other funds holding KYTX

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return

SIC

Samalin Investment Counsel Chappaqua, New York $320M AUM 20.87% 1-Year Est. Return

CAI

Capital Advisors Inc Tulsa, Oklahoma $6.8B AUM 26.96% 1-Year Est. Return

GWM

GSB Wealth Management Guilford, Connecticut $498M AUM 27.51% 1-Year Est. Return

Y-Intercept (HK)'s KYTX Position: Q2 2026 in Review

Y-Intercept (HK) increased its Kyverna Therapeutics (KYTX) stake by 111% in Q2 2026, buying an estimated $1.13M and bringing the position to 242,387 shares worth $2.16M. The position accounts for 0.04% of the portfolio, ranked #655.

Y-Intercept (HK) first reported a position in KYTX in Q2 2025 and has held it in 3 quarters since. 21 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

Y-Intercept (HK) held 242,387 shares of Kyverna Therapeutics worth $2.16M as of Q2 2026.
Y-Intercept (HK) bought 127,546 Kyverna Therapeutics shares in Q2 2026, an estimated $1.13M.
Kyverna Therapeutics made up 0.04% of Y-Intercept (HK)'s portfolio in Q2 2026, its #655 holding.
Y-Intercept (HK) first reported a position in Kyverna Therapeutics in Q2 2025 and has held it in 3 quarters since.
21 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.